Mitoxantrone
- Generic Name
- Mitoxantrone
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML
- Conditions
- Relapsed/Refractory Acute Myeloid LeukaemiaMyeloid Malignancy
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 34
- Registration Number
- NCT06434662
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
- Conditions
- LeukemiaMonocytic LeukemiaMyeloid Leukemia
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 30
- Registration Number
- NCT06429449
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukaemia
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Zhongnan Hospital
- Target Recruit Count
- 154
- Registration Number
- NCT06345365
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳The Central Hospital of Huanggang, Huanggang, Hubei, China
🇨🇳Shiyan Taihe Hospital, Shiyan, Hubei, China
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
- Conditions
- Acute Myeloid Leukemia in Children
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Target Recruit Count
- 60
- Registration Number
- NCT06262438
- Locations
- 🇳🇱
Princess Máxima Center for pediatric oncology, Utrecht, Netherlands
Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL
- Conditions
- Angioimmunoblastic T-cell Lymphoma
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Huijing Wu
- Target Recruit Count
- 30
- Registration Number
- NCT06224842
- Locations
- 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
- Conditions
- AML, ChildhoodAcute Myeloid Leukemia
- Interventions
- Drug: Recombinant Human Granulocyte Colony-Stimulating Factor
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Children's Hospital of Soochow University
- Target Recruit Count
- 500
- Registration Number
- NCT06221683
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳XiangYa Hospital Central South University, Changsha, Hunan, China
🇨🇳Children's Hospital of Soochow University, Suzhou, Jiangsu, China
Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies
- Conditions
- B-cell Acute Lymphoblastic LeukemiaB-cell Lymphoma Refractory
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 28
- Registration Number
- NCT06220097
- Locations
- 🇨🇳
Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China
Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2023-12-05
- Target Recruit Count
- 24
- Registration Number
- NCT06156761
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Relapsed Adult AMLRefractory AML
- Interventions
- Drug: Granulocyte Colony-Stimulating Factor
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Medical College of Wisconsin
- Registration Number
- NCT06007911
- Locations
- 🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 20
- Registration Number
- NCT05990985
- Locations
- 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.